Álvaro Gómez
Álvaro is a physician researcher and postdoctoral fellow at the Clinical Epidemiology Division, Karolinska Institutet, focusing on systemic autoimmune rheumatic diseases, particularly systemic lupus erythematosus. His research examines how biological, social, economic, and psychological factors influence long-term outcomes, including somatic and mental health comorbidities.
Álvaro uses national Swedish registers, clinical cohorts, randomised controlled trials, survey-based studies, and systematic reviews to study prognosis and treatment outcomes. This includes work on B-cell–targeting biologics and the impact of (non-)pharmacological interventions on patient-reported outcomes in lupus.
Álvaro is part of the Junior Faculty steering group at the Clinical Epidemiology Division at KI, and member of the EMEUNET Country Liaison Sub-Committee.
| Oral 0772 | Sunday, 26.10.25 09:45 Plenary Session: Plenary I Presenting author: M Petri (USA) Title: Redefining When to Biopsy the Kidney in Patients with SLE  This study challenges the current 0.5 g/g UPCR threshold for kidney biopsy, showing that among SLE patients without prior lupus nephritis and UPCR between 0.25 and 0.499 g/g, 69% had lupus nephritis, 61% of which required mycophenolate mofetil. |
| Oral 0855 | Monday, 27.10.25 10:00 Abstract Session: Antiphospholipid syndrome Presenting author: J Salmon (USA) Title: Certolizumab Pegol to Prevent Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome and Lupus Anticoagulant (IMPACT): Results from Ongoing Recruitment of a Prospective, Single-Arm, Open-Label, Phase 2 Trial This study presented updated results of the IMPACT trial, showing the effectiveness of certolizumab in preventing placenta-mediated adverse pregnancy outcomes in women with high-risk APS. |
| Oral 0880 | Monday, 27.10.25 10:15 Abstract Session: Systemic Sclerosis & Related Disorders – Clinical II Presenting author: N Iandini (Italy) Title: Detecting Interstitial Lung Disease and Identifying Extensive Disease on Chest Computed Tomography in Patients with Systemic Sclerosis: Cut-Offs for Lung Texture Analysis and its Prognostic Implications This study derived and validated cut-offs for detecting ILD and extensive ILD in chest CT using automated post-processing software, showing performance comparable to visual evaluation by radiologists. |
| Oral 0884 | Monday, 27.10.25 11:15 Abstract Session: Systemic Sclerosis & Related Disorders – Clinical II Presenting author: A Pecher (Germany) Title: Risk Score for Early Mortality to stratify for Intensive SSc Therapy Using the large EUSTAR cohort, this study developed RESIST, a mortality risk score based on eight routinely collected variables in patients with SSc. |
| Oral 1722 | Tuesday, 28.10.25 08:00 Plenary Session: Plenary III Presenting author: S Garg (USA) Title: Defining Safe Hydroxychloroquine Blood Levels: Time to Switch to Precision Monitoring for Optimized Lupus Care This large multicohort study supported hydroxychloroquine blood monitoring in SLE and proposed a therapeutic range (750 – 1150 ng/mL), showing that lower levels were linked to active disease and higher levels to toxicity. |
| Oral 2600 | Tuesday, 28.10.25 13:45 Abstract Session: Systemic Lupus Erythematosus – Etiology and Pathogenesis Presenting author: N Sugiarto (USA) Title: Deconstructing Lupus Nephritis Kidney Tissue at Single-Cell Resolution This study built an atlas of kidney tissue cell types in lupus nephritis by integrating single-cell and single-nuclear profiles from kidney biopsies with single-cell blood profiles, enabling the identification of cell states associated with activity and chronicity. |